CN115697403A - Il-6/il-6r抗体的组合物及其使用方法 - Google Patents

Il-6/il-6r抗体的组合物及其使用方法 Download PDF

Info

Publication number
CN115697403A
CN115697403A CN202180034449.8A CN202180034449A CN115697403A CN 115697403 A CN115697403 A CN 115697403A CN 202180034449 A CN202180034449 A CN 202180034449A CN 115697403 A CN115697403 A CN 115697403A
Authority
CN
China
Prior art keywords
antibody
composition
ser
weight
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180034449.8A
Other languages
English (en)
Chinese (zh)
Inventor
K·谢鲁拜
G·塞罗内
V·A·帕莱杰瓦拉
J·S·雅各布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tiziana Life Sciences Ltd
Original Assignee
Tiziana Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tiziana Life Sciences Ltd filed Critical Tiziana Life Sciences Ltd
Publication of CN115697403A publication Critical patent/CN115697403A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180034449.8A 2020-03-10 2021-03-10 Il-6/il-6r抗体的组合物及其使用方法 Pending CN115697403A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062987837P 2020-03-10 2020-03-10
US62/987837 2020-03-10
US202063006612P 2020-04-07 2020-04-07
US63/006612 2020-04-07
US202063014800P 2020-04-24 2020-04-24
US63/014800 2020-04-24
PCT/EP2021/056113 WO2021180821A2 (en) 2020-03-10 2021-03-10 Compositions of il-6/il-6r antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
CN115697403A true CN115697403A (zh) 2023-02-03

Family

ID=74871406

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180034449.8A Pending CN115697403A (zh) 2020-03-10 2021-03-10 Il-6/il-6r抗体的组合物及其使用方法

Country Status (8)

Country Link
US (2) US20210284743A1 (cg-RX-API-DMAC7.html)
EP (1) EP4117727A2 (cg-RX-API-DMAC7.html)
JP (1) JP2023517611A (cg-RX-API-DMAC7.html)
CN (1) CN115697403A (cg-RX-API-DMAC7.html)
AU (1) AU2021234094A1 (cg-RX-API-DMAC7.html)
CA (1) CA3169827A1 (cg-RX-API-DMAC7.html)
IL (1) IL296276A (cg-RX-API-DMAC7.html)
WO (1) WO2021180821A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4121455A1 (en) * 2020-03-18 2023-01-25 Vitaeris Inc. Use of anti-il-6 antibody, e.g., clazakizumab for treatment/prevention of ards associated with coronavirus (covid-19) infection
WO2022006051A1 (en) * 2020-06-29 2022-01-06 Anovent Pharmaceutical (U.S.), Llc Formulation of tocilizumab and method for treating covid-19 by inhalation
US20230227555A1 (en) * 2020-07-30 2023-07-20 Tiziana Life Sciences Plc Cd-3 antibodies for the treatment of coronavirus
US12552861B2 (en) * 2021-10-08 2026-02-17 National Taiwan University Monoclonal antibody
WO2025122924A1 (en) * 2023-12-07 2025-06-12 Tourmaline Bio, Inc. Methods for the prevention and treatment of long covid and related symptoms

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102089326A (zh) * 2008-05-13 2011-06-08 诺维莫尼公司 抗白细胞介素-6/白细胞介素-6受体的抗体及其使用方法
CN102292107A (zh) * 2008-11-25 2011-12-21 奥尔德生物制药公司 增加白蛋白和/或减少crp的il-6拮抗剂
CN102740888A (zh) * 2009-11-24 2012-10-17 奥尔德生物制药公司 Il-6抗体及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4654210A (en) 1979-04-26 1987-03-31 Ortho Pharmaceutical Corporation Methods and compositions using complement fixing monoclonal antibody to human T cells
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4978745A (en) 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
DE69032484D1 (de) 1989-10-27 1998-08-20 Arch Dev Corp Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
WO2003068260A1 (fr) * 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
US7713440B2 (en) 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
JP5419709B2 (ja) * 2007-01-09 2014-02-19 ワイス・エルエルシー 抗il−13抗体製剤およびその使用
CA3290174A1 (en) * 2015-03-30 2026-03-02 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
EP3504241B1 (en) * 2016-08-29 2024-05-15 Tiziana Life Sciences PLC Anti-cd3 antibody formulations
CA3031691A1 (en) 2016-09-13 2018-03-22 Rasna Research Inc. Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
BR112019006853B1 (pt) * 2016-10-31 2021-08-24 Fresenius Kabi Deutschland Gmbh Composição farmacêutica líquida, seu método de fabricação, seu uso, kit e dispositivo de liberação de fármaco que a compreendem e método de fabricação do dito dispositivo
US10093731B2 (en) * 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102089326A (zh) * 2008-05-13 2011-06-08 诺维莫尼公司 抗白细胞介素-6/白细胞介素-6受体的抗体及其使用方法
CN102292107A (zh) * 2008-11-25 2011-12-21 奥尔德生物制药公司 增加白蛋白和/或减少crp的il-6拮抗剂
CN102740888A (zh) * 2009-11-24 2012-10-17 奥尔德生物制药公司 Il-6抗体及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SUXIN WAN, M.D. 等: "Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)", MEDRXIV, 12 February 2020 (2020-02-12), pages 1 - 13 *
国家知识产权局抗击新型冠状病毒肺炎专利信息分析课题组: "抗击新型冠状病毒肺炎专利信息研报", pages 8, Retrieved from the Internet <URL:https://www.cnipa.gov.cn/art/2020/2/14/art_53_118212.html> *

Also Published As

Publication number Publication date
WO2021180821A2 (en) 2021-09-16
AU2021234094A1 (en) 2022-09-15
JP2023517611A (ja) 2023-04-26
US20260125483A1 (en) 2026-05-07
US20210284743A1 (en) 2021-09-16
CA3169827A1 (en) 2021-09-16
IL296276A (en) 2022-11-01
WO2021180821A3 (en) 2021-10-14
EP4117727A2 (en) 2023-01-18

Similar Documents

Publication Publication Date Title
JP7575526B2 (ja) Il-4r阻害剤の投与によるアレルギー処置方法およびアレルゲン特異的免疫療法の向上方法
US20260125483A1 (en) Compositions of il-6/il-6r antibodies and methods of use thereof
CN113354732B (zh) 针对埃博拉病毒糖蛋白的人抗体
DK2187964T3 (en) HIGH AFFINE HUMAN ANTIBODIES FOR HUMAN NERVOUS FACTOR
RU2732032C2 (ru) Антитела с двойной специфичностью
JP5872757B2 (ja) ヒト化抗b因子抗体
CN107261139A (zh) 治疗或预防胆固醇相关疾病的方法
KR20170098888A (ko) 인플루엔자 헤마글루티닌에 대한 인간 항체
CN114173819A (zh) 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
KR20180053682A (ko) 인터루킨-33(il-33)-매개된 질환과 관련된 바이오마커 및 이의 용도
CN114504651A (zh) 抗体、用途和方法
KR20190064636A (ko) 항-o1 항체 및 이의 용도
US10689441B2 (en) Anti—TLR4 antibodies and methods of use thereof
CN116406274B (zh) 用于治疗冠状病毒的cd3抗体
US20240092882A1 (en) Method of treating an allergy with allergen-specific monoclonal antibodies
AU2018325842A1 (en) Polypeptide and antibody bound to polypeptide
US20260125471A1 (en) Subcutaneous administration of antibodies for the treatment of disease
RU2781553C2 (ru) Антитела к pac1 и варианты их применения
CN115768878A (zh) 用于增强嵌合抗原受体(car) t细胞疗法的组合物和方法
HK40074936A (en) Antibodies, uses &amp; methods
HK40042519A (en) Antibodies, uses and methods
TW202130364A (zh) 以介白素24或介白素20拮抗劑治療組織纖維化和/或損傷和/或器官衰竭

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination